BioLife Solutions, Inc. (BLFS)

Market Cap	1.27B
Revenue (ttm)	146.96M
Net Income (ttm)	-46.03M
Shares Out	46.39M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	876,300
Open	25.58
Previous Close	26.11
Day's Range	25.13 - 28.63
52-Week Range	14.50 - 28.88
Beta	1.92
Analysts	Strong Buy
Price Target	29.00 (+5.88%)
Earnings Date	Nov 12, 2024

About BLFS

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproductio...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 22, 1989
• Employees: 414
• Stock Exchange: NASDAQ
• Ticker Symbol: BLFS
• Website: https://www.biolifesolutions.com

Financial Performance

In 2023, BioLife Solutions's revenue was $143.27 million, a decrease of -11.43% compared to the previous year's $161.76 million. Losses were -$66.43 million, -52.49% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price forecast is $29.0, which is an increase of 5.88% from the latest price.

Price Target

$29.0

(5.88% upside)

Analyst Consensus: Strong Buy